Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy

Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson’s disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and...

Descripción completa

Detalles Bibliográficos
Autores principales: Moretti, Davide Vito, Binetti, Giuliano, Zanetti, Orazio, Frisoni, Giovanni Battista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051815/
https://www.ncbi.nlm.nih.gov/pubmed/24940065
http://dx.doi.org/10.2147/NDT.S64015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051815/
https://www.ncbi.nlm.nih.gov/pubmed/24940065
http://dx.doi.org/10.2147/NDT.S64015

Ejemplares similares